PSC
VIVO

Piper Sandler & Co’s Meridian Bioscience Inc VIVO Stock Holding History

Piper Sandler & Co’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-25,000
Closed -$466K – 134
2015
Q2 		$466K Buy
+25,000
New +$464K 0.28% 37

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Piper Sandler & Co's VIVO Position: Q3 2015 in Review

Piper Sandler & Co sold out of Meridian Bioscience Inc (VIVO) in Q3 2015, closing a stake of 25,000 shares — an estimated $466K sold.

Piper Sandler & Co first reported a position in VIVO in Q2 2015 and held it in 1 quarter. The position peaked at $466K in Q2 2015. 175 funds tracked by Wall St. Rank hold VIVO as of Q3 2015.

  • Piper Sandler & Co reported no remaining Meridian Bioscience Inc position as of Q3 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 25,000 Meridian Bioscience Inc shares in Q3 2015, an estimated $466K.
  • Piper Sandler & Co first reported a position in Meridian Bioscience Inc in Q2 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Meridian Bioscience Inc position peaked at $466K in Q2 2015.
  • 175 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2015.

Based on Piper Sandler & Co's 13F filing for Q3 2015, filed 16 Nov 2015.